Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

A collaborative study, published on January 21 on Nature Communications, presents a novel strategy to improve the ...

Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

This impacts the proliferation, migration, apoptosis and metabolism of tumor cells; hypoxia is considered a key contributor to chemoresistance in cancer cells.